

# ADA TV

Returning for the 4th year ADA TV is at the 2019 ADA Annual Meeting in San Francisco, CA.

The channel serves to raise the visibility of best practices in the field, as well as to highlight collaborations between diverse institutions including university departments, research institutions and private sector organizations.

ADA TV will be onsite at the Moscone Center, to interview key speakers and to hear your views on hot topics.

## ADA TV Highlights

### AALBORG UNIVERSITY HOSPITAL

Improving the quality of life and life spans for people with Diabetes in North Denmark. Steno Diabetes Center North Denmark was a reality since the 1st of January 2018 and is one of five Steno Diabetes Centers in Denmark which is the result of a public-




private partnership and grant between the Novo Nordisk Foundation and the public health care system in Denmark.

**Aalborg University Hospital/Steno Diabetes Center North Denmark**

### sweetch

Sweetch is an artificial intelligence based platform for prediction, prevention, and outcome improvement of Type 2 Diabetes. Sweetch



is working with US healthcare provider WellSpan to provide WellSpan employees with free access to the Sweetch mobile phone app.

**Sweetch**



### Icahn School of Medicine at Mount Sinai

Gabrilove Division of Endocrinology, Diabetes, and Bone Disease at the Mount Sinai Health System do. Their physicians and scientists specialize in advancing medicine, conducting



research and delivering high-quality care to patients who live with diabetes. This video will give you a high-level glimpse into their innovative research on beta cell regeneration as well as diabetes and pregnancy. They're proud to be one of four sites nationwide to receive NIH funding for the first artificial pancreas study in pregnant women, and are committed to creating strategies to prevent, reverse and cure this complex disease.

**Mount Sinai Health System, Icahn School of Medicine**

## Where to watch ADA TV



@WebsEdge\_Health @ADA\_DiabetesPro #ADA2019



WebsEdgeHealth



WebsEdgeHealth

Watch ADA TV around the convention center and at the following hotels: San Francisco Marriott Marquis **Ch60** Hilton San Francisco Union Square **Ch52** Hyatt Regency San Francisco **Ch79** Westin St. Francis **Ch59** Parc 55 **Ch51** InterContinental San Francisco **Ch67** Fairmont San Francisco **Ch79** Grand Hyatt San Francisco **Ch62**

ADA TV is produced by [www.websedge.com](http://www.websedge.com)



The team at Gan & Lee Pharmaceuticals USA are a close-knit, passionate group, focused on improving lives through new treatment options for people living with diabetes. Gan & Lee Pharmaceuticals is a China-based company with a range of insulin biosimilars, already helping patients in China based on their high quality and relatively low cost. As the price of insulin increases in the western world, and increasing numbers of patients don't get access to the treatment they need, the team in the USA are working on Phase 3 clinical trials to bring these products to a broader market. This highly qualified and passionate team are doing everything they can to ensure these products meet the stringent requirements of agencies across Europe and the USA, working hard to improve the lives of people with diabetes worldwide.

**Gan and Lee Pharmaceuticals USA**



50 years ago, scientists discovered a glucose metabolism enzyme in mice pancreas, which showed very different enzyme kinetic properties from known hexokinase, a

glucose process enzyme. Glucokinase, as a glucose sensor, plays a central role in glucose homeostasis, which controls the human blood glucose level in a very narrow range of 4-6.5 mmol/L. Since then, researchers have been working to control Glucokinase in diabetes patients using Glucokinase Activators, with little success. However, a new approach by Shanghai-based Hua Medicine has great promise.

**Hua Medicine**



Through close collaboration with some of China's top diabetes professionals, as well as internationally renowned diabetes experts, Hua Medicine has reached a

very good understanding on how to design the right Glucokinase Activator for diabetes treatment. Hua Medicine are changing the paradigm of diabetic treatment from simply lowering blood glucose to actually repairing defects of glucose regulation in the body as well as remodelling glucose homeostasis. The overall aim is to develop the next generation in Type 2 Diabetes treatment.

**Hua Medicine**



"Patient First, innovation driven, Novel medicine" is the mission of Hua Medicine, one of China's leading biotech companies. While focusing on building up a sound scientific

foundation for their innovative medicine, Hua has worked closely with leading physicians and top clinical study organizations across China to ensure a high standard & high quality of drug development. During Phase 3 trials of their novel Glucokinase Activator, Hua and it's collaborators are working hard to ensure ongoing value for patients.

**Hua Medicine**



Diabetes has become a disaster with more than 400 million individuals Type 2 Diabetes (T2D) globally. Though there are many diabetes drugs, the key causes of T2D, insulin

resistance and pancreas islet dysfunction, have still not been addressed successfully. However this could change as the first Glucokinase Activator (GKA) enters phase III trials. With the potential to revitalize the function of the Beta-cell, Dorzagliatin could open the door to a new, more personalised approach to diabetes treatment worldwide.

**Hua Medicine**



The introduction of glp-1 receptor agonists has been one of the most significant breakthroughs in diabetes

therapy in the past decade. However, while GLP-1R agonists produce substantial weight loss in animal models, they only provide modest weight loss in humans. It was this disconnect that inspired Carmot Therapeutics to look further into the biology of GLP-1. The insights gained from these studies put Carmot Therapeutics on a path to develop better and more efficacious therapies for the treatment of diabetes, obesity and fatty liver disease. To identify drugs with the desired attributes, Carmot Therapeutics turned to the drug discovery technology called Chemotype Evolution. Chemotype Evolution was invented by Carmot and has revolutionized the ability to make and test new drug molecules. This allows to rapidly explore novel chemistry in the search for drug molecules with specific biological properties. Using this technology Carmot Therapeutics has identified compounds that modulate both GLP and GIP biological pathways in ways that the natural hormones are not capable of.

**Carmot Therapeutics**



Hadassah University Hospital have recently demonstrated that a new family of drugs can dramatically impact patient CV and renal

outcomes and have a positive effect on these dangerous complications. The results of the recent trials suggest that very early treatment of diabetes or even pre-diabetes with these drugs can dramatically change the future of over 600 million people and even more patients with diabetes by 2040. Drug therapy, however, as good as it is, will never completely override the damage induced by obesity, metabolic syndrome and diabetes. Moreover, early diagnosis of diabetes might still be too late to prevent long term complications of diabetes including CVD and cancer.

**Hadassah University Hospital**



The Patient-Centered Outcomes Research Institute (PCORI) works with stakeholders across the healthcare

community to generate and disseminate evidence that will help patients and those who care for them make better-informed healthcare decisions. PCORI funds comparative clinical effectiveness research (CER), studies that compare two or more treatments or care approaches to see which work best, for whom, to improve outcomes patients care about. PCORI focuses on the conditions that impose the highest burdens on individuals, their families, and the healthcare system, including diabetes. PCORI takes a unique approach to CER: "research done differently." PCORI engages patients and other stakeholders from selecting research topics to study and projects to fund through disseminating study results. The goal is to make it more likely that the results of PCORI's funded studies will be useful, relevant, and more likely to be taken up in practice.

**The Patient-Centered Outcomes Research Institute (PCORI)**



**WORLD DIABETES FOUNDATION**

Diabetes is hitting developing countries the hardest. The World Diabetes Foundation helps developing countries improve diabetes prevention and care by supporting partners at every level - from grassroots organisations to national, regional and global entities. In Guinea, the WDF partners with Naby Baldé, regional chair of the IDF Africa.



The WDF has supported more than 555 projects in 116 countries to date – projects that continue to benefit local communities long after WDF funding ends, and together are acting as a catalyst for global change.

**World Diabetes Foundation**



In 2012, a significant gift from the Osteopathic Heritage Foundation (OHF) helped form the Diabetes Institute, bringing together all aspects of diabetes research, clinical care, community outreach, and professional training at Ohio University. This gift supported the growth of diabetes research infrastructure including hiring six new faculty in basic and applied sciences with strong research programs in diabetes and purchasing key equipment for conducting diabetes research.

**Ohio University Diabetes Institute**



Western Sydney Diabetes (WSD) in Sydney, Australia, is co-led by Western Sydney Local Health District (WSLHD), Western Sydney Primary Health Network (WSPHN), Diabetes NSW and ACT, and PricewaterhouseCoopers (PwC).



People living in western Sydney are twice as likely to develop Type 2 Diabetes compared with people living in Seaside and the Northern Suburbs. WSD has made 'beating diabetes together' a high priority for the Western Sydney Local health District, which

serves about 1 million people. WSD has developed a framework of action that includes primary prevention and secondary prevention and better integrated care across the community and acute hospital services.

**Western Sydney Diabetes**



الجمعية القطرية للسكري  
Qatar Diabetes Association

The Qatar Diabetes Association

leads efforts in Qatar and the Middle East to promote the prevention, care, and management of diabetes. The Association's mission is to provide care for people suffering from diabetes and those who are at risk of developing it, so that they can lead full and productive lives.



Through its various health-education activities and programs, QDA provides information, outreach, and support to people with diabetes and their families and raises public awareness of the causes of the condition and means to prevent it.

**Qatar Diabetes Association (QDA)**



Singapore National Eye Centre  
SingHealth

The Singapore National Eye Centre's Medical

Retina Department manages conditions affecting the retina that are not amenable to surgical treatment. Non-surgical treatment options offered include laser and medications. A wide range of conditions are currently under the care of the department, the most common of which include diabetic eye disease. Retinal photography is the most common and cost-effective Diabetic Retinopathy screening method, where photographs of retinal scans are assessed and graded by trained eye doctors, optometrists, or professional graders. With increasing numbers of diabetics worldwide, the manual assessment of millions of photographs will become unsustainable in the future. SERI's research team, in collaboration with the NUS School of Computing, has developed a state-of-the-art artificial intelligence (AI) system to automatically assess retinal photographs and replace human graders, which can significantly reduce public health care costs while maintaining its standards.

**Singapore National Eye Centre**



New technology in diabetes management is bringing the reality of clinical studies into routine clinical care.

For the first time, insulin titration tools such as d-Nav from Hygieia allows all insulin users to reach their target HbA1c via personalized insulin dosing.

**Hygieia**



The Sentara Norfolk General Hospital (SNGH) and Eastern Virginia Medical School (EVMS) Diabetes



Programs located in Norfolk, Virginia, deliver exemplary patient care, conduct innovative research, and train future experts in the quest to prevent, treat and cure diabetes. The EVMS Strelitz Diabetes Center provides state of the art treatment of diabetes and its complications in the outpatient, inpatient and community settings.



The EVMS-Sentara Cardiovascular Diabetes Program provides a unique comprehensive, multidisciplinary diabetes care for inpatients with cardiovascular disease. Both the SNGH Diabetes & Endocrinology service and Cardiology & Heart Surgery Services, who are run collaboratively with EVMS, are nationally ranked by the US News and World Report as 31st and 32nd respectively. Clinical research studies and trials being conducted include investigating better ways of treating diabetes in patients with heart disease, the mechanisms of diabetic neuropathy and newer ways of treating them, the role of inflammation in the development of obesity and diabetes, and new biomarkers for Type 1 Diabetes to explore the role of viruses in triggering the disease's development. Elias S. Siraj, MD leads the diabetes programs at both EVMS and SNGH and he has a special interest in improving outcomes for patients with diabetes and cardiovascular diseases.

**The Sentara Norfolk General Hospital (SNG) and Eastern Virginia Medical School (EVMS) Diabetes Programs**

**PromarkerD**  
CHANGING LIVES

PromarkerD is a new generation of predictive

medtech to help the 30 million people (in the USA alone) with Type 2 Diabetes, and their health care providers. PromarkerD saves lives and can improve patient livelihood through a simple blood test.



PromarkerD can be run regularly to monitor patient risk, thereby determining patient Diabetic Kidney Disease (DKD) health, and allowing interventions that can delay or avoid the cost and time associated with DKD related dialysis and surgery.

**Proteomics International, Australia**

**SANOFI**

Sanofi is dedicated to supporting people through

their health challenges. Being a global biopharmaceutical company focused on human health. Preventing illness with vaccines, provide innovative treatments to fight pain and ease suffering. They stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

**Sanofi**



Gestational diabetes is an early indicator of possible metabolic dysfunction in early

life. There is a known continuum of effects and risks from having gestational diabetes. While much of the current efforts are rightly concerned with the acute risks of gestational diabetes on the pregnancy and immediate post-partum risks for mother and child. In GUSTO, the Singapore Institute for Clinical Sciences has found that the long-term risks of gestational diabetes are perhaps, equally alarming. In our mums with past gestational diabetes – approximately 4 – 5 in 10 get some degree of glucose impairment within a short 5 years post-partum.

**A\*STAR Singapore Institute for Clinical Sciences**

**HDZ NRW**  
UKRUB UNIVERSITÄTSSKLINIKUM DER RUHR-UNIVERSITÄT BOCHUM

Heart failure is a common comorbidity in the western world.

A patient with diabetes is at risk for developing heart failure; a patient with heart failure frequently develops metabolic disease.



The HDZ NRW is specialized in treating patients of all ages from the very beginning to end stage heart failure.

Not only treatment of patients is in focus at HDZ NRW, but also research activities yield in understanding common disease pathways resulting in heart failure.

**Diabetes Centre, Heart and Diabetes Centre NRW**



The Harold Hamm Diabetes

Center, located in Oklahoma City, is committed to curing diabetes and ending the diabetes pandemic in the 21st century. It is among the world's largest and most comprehensive institutions of its kind, integrating top-flight academic research with clinical care and disease prevention. Top researchers and pediatric doctors are coming together at Harold Hamm Diabetes Center to study the impact of nutrition, beginning at conception and a child's first 1,000 days to 2 years of life, in order to shape long-lasting health. Research in the fields of neuroscience, gut function, adipose development, pancreas, and liver health provide powerful insights into how nutrition and genomics shape future outcomes.

**Harold Hamm Diabetes Center**



The Gabriel Cabra Bildirici Diabetes Center was

established by the Sanz Medical Center-Laniado Hospital to solve this problem and to take into account the needs of the patient and his/her family, with the goal of grouping all the required tests, treatments, and medical experts in one central location for the treatment of diabetes. With this overall vision of providing convenient service and improving the patients' quality of life, the Diabetes Center provides all the necessary tests and physicians in a wide range of specialties under one roof, thus enabling comprehensive treatment of diabetes. The Bildirici Diabetes Center is the first and only such center in Israel. It operates according to an innovative approach that aims to streamline and shorten the medical process for diabetes patients, thus assisting them to cope with the disease and its side-effects, and to adjust to a new lifestyle.

**Sanz Medical Center-Laniado Hospital**



As an integral part of research at Sidra Medicine, the Diabetes

and Metabolic Disorders Center was created to serve as a catalyst to promote innovative



research on both Type 1 and Type 2 Diabetes and related metabolic disorders. The primary goal is to gain fundamental knowledge and enhance the understanding of environmental, molecular, and genetic causes of the disease.

**Sidra Medicine**

**ADA TV online!**



@WebsEdge\_Health @ADA\_DiabetesPro #ADA2019



WebsEdgeHealth



WebsEdgeHealth

**Watch ADA TV around the convention center and at selected hotels.  
ADA TV is produced by www.websedge.com**